Upstream Bio, Inc. (UPB) News
Follow Upstream Bio, Inc. (UPB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Upstream Bio shares rise after phase 2 severe asthma primary endpoint
Upstream Bio shares rose after its severe asthma treatment met the primary endpoint in a phase 2 trial. The stock gained 9.3% to $6.57 in premarket trading; it was down 78% year to date at market close.
EQUITY | Sep 08, 2026, 10:29 AM UTC
L
UPB presents Phase 2 VALIANT trial results at ERS Congress 2026
Upstream Bio presented results from its Phase 2 VALIANT trial of verekitug for severe asthma in an oral presentation at ERS Congress 2026.
GEOPOLITICS | Sep 08, 2026, 07:38 AM UTC
L
HC Wainwright maintains $36 price target for Upstream Bio
HC Wainwright & Co. maintained its $36.00 per-share price target for Upstream Bio, per Benzinga ratings actions (TradingView News).
EQUITY | Sep 02, 2026, 11:35 AM UTC
M
Upstream Bio outlines Phase 3 plan for verekitug
Upstream Bio announced pivotal Phase 3 plans for verekitug, including a 400mg subcutaneous dose every 12 weeks and two placebo-controlled trials totaling about 1,500 patients.
REGULATION | Sep 01, 2026, 11:13 AM UTC
M
Upstream Bio outlines Phase 3 plans for verekitug in asthma and CRSwNP
Upstream Bio says it will study 400 mg verekitug every 12 weeks versus placebo in severe asthma and CRSwNP, using one pivotal Phase 3 trial per indication after FDA discussions.
REGULATION | Sep 01, 2026, 11:08 AM UTC
M
Upstream Bio announces Phase 3 plans for Verekitug in two indications
Upstream Bio said it has pivotal Phase 3 development plans for Verekitug in severe asthma and CRSwNP.
EQUITY | Sep 01, 2026, 11:02 AM UTC